Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 5 versus THYROLAR 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 5 versus THYROLAR 2.
THYROLAR-0.5 vs THYROLAR-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone replacement; L-thyroxine (T4) is converted to active triiodothyronine (T3) which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate and oxygen consumption.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
Initial dose 0.5 tablets (30 mg T4/7.5 mg T3) orally once daily, titrated every 2-4 weeks based on TSH, free T4, and free T3 levels; usual maintenance 0.5-2 tablets (30-120 mg T4/7.5-30 mg T3) once daily.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
None Documented
None Documented
For liothyronine (T3): approximately 1.5-2.5 days; for levothyroxine (T4): approximately 6-7 days. In hyperthyroidism, half-life may be shortened; in hypothyroidism, prolonged.
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
Renal (approximately 40-50% as unchanged drug and conjugates), fecal (approximately 20-30% via biliary elimination), with the remainder metabolized and eliminated via urine and feces.
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone